Table 1.
Characteristic | n | Bone marrow positive | P value | |
n | % | |||
Total | 157 | 84 | 53 | - |
Menopausal status | 0.3 | |||
Premenopausal | 72 | 42 | 58 | |
Postmenopausal | 85 | 42 | 49 | |
Tumor size | 0.6 | |||
ypT0 | 24 | 10 | 44 | |
ypT1 | 61 | 33 | 54 | |
ypT2–ypT4 | 73 | 41 | 56 | |
Nodal status | 0.5 | |||
ypN negative | 75 | 38 | 51 | |
ypN positive | 82 | 46 | 56 | |
Estrogen receptor status | 1.0 | |||
Negative | 39 | 21 | 54 | |
Positive | 118 | 63 | 53 | |
Progesterone receptor status | 0.7 | |||
Negative | 68 | 35 | 52 | |
Positive | 89 | 49 | 55 | |
HER2 status | ||||
Negative (score 0/+1 by immunohistochemistry) | 115 | 63 | 54 | 0.7 |
Positive (score +2/+3 by immunohistochemistry) | 39 | 20 | 51 | |
Grading | 0.9 | |||
I–II | 109 | 58 | 53 | |
III | 41 | 21 | 51 | |
Histology | 0.2 | |||
Ductal | 97 | 48 | 49 | |
Lobular | 33 | 17 | 52 | |
Others | 27 | 19 | 70 | |
Primary systemic therapy | 0.3 | |||
Chemotherapy | 142 | 78 | 55 | |
Hormonal therapy | 15 | 6 | 40 | |
Response to neoadjuvant systemic therapya | <0.05c | |||
Pathological complete remission | 24 | 10 (4)b | 42 (17)b | |
Partial remissiond | 87 | 42 (11)b | 48 (13)b | |
Stable disease | 40 | 27 (2)b | 68 (5)b | |
Progressive disease | 5 | 4 (0)b | 80 (0)b |
aNot including apoptotic cells (see Table 2). bNumber (percentage) of patients with only apoptotic cells. cComplete remission + partial remission (46%) versus stable disease + progressive disease (69%). dPartial remission also includes patients with clinical complete remission but pathological partial remission.